Synthetic Peptide Microarray Screening for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of antibiotic-resistant bacteria has limited the effectiveness of traditional antibiotics, necessitating the development of alternative antimicrobial agents, with antimicrobial peptides (AMPs) emerging as promising candidates due to their specificity and rapid action against bacterial cell membranes, but existing methods for discovering new AMPs are inefficient.
Innovation Solution
A high-throughput screening method using a library of synthetic peptides attached to a silicon wafer coated with a photoresist and photoacid generator, where fluorescently labeled bacterial cells are incubated with the peptide microarray to identify peptides bound to the cells, and those inhibiting bacterial growth are selected for further use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then treatment options are limited, but antibiotic-resistant bacteria reduce effectiveness
Solution Approach 1:
The patent changes the fundamental parameter of antimicrobial mechanism from traditional antibiotic targets (proteins, enzymes, metabolic pathways) to physical disruption of bacterial cell membranes through cationic amphipathic peptides. This parameter change bypasses antibiotic resistance mechanisms that have evolved against conventional antibiotics.
Solution Approach 2:
The patent segments the approach to antimicrobial therapy by using multiple distinct peptide sequences with different amino acid compositions but shared cationic amphipathic properties. This segmentation allows for targeted activity against specific resistant bacteria while maintaining broad applicability.
2Reliability
If antimicrobial peptides are designed with amino acid substitutions to be cationic and amphipathic, then selectivity towards bacterial membranes is improved, but discovery methods become inefficient
Solution Approach 1:
The patent applies preliminary action by pre-designing peptide libraries with established cationic amphipathic characteristics before screening. This preliminary structuring ensures that all peptides in the library possess the fundamental properties needed for bacterial membrane selectivity, allowing rapid screening focused on activity rather than basic property verification.
Solution Approach 2:
The patent changes the discovery approach from random screening to targeted screening of peptides with specific physical-chemical parameters (cationic charge, amphipathic structure). This parameter-based selection dramatically increases discovery efficiency while maintaining high selectivity for bacterial membranes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the rapid identification of synthetic antimicrobial peptides effective against resistant bacteria like Mycobacterium abscessus and other pathogens, with minimal toxicity and stability in human serum, providing a potent alternative to traditional antibiotics.
Implementation Method 1
fluorescently labeled bacterial cells are incubated with the peptide microarray to identify peptides bound to the cells
Implementation Method 2
a high-throughput screening method using a library of synthetic peptides attached to a silicon wafer coated with a photoresist and photoacid generator
Data Source
AI summary
Synthetic antimicrobial peptides, compositions comprising thereof, and methods of use for modulating one or more symptoms of an infection in a subject are disclosed. In some aspects, the infection is caused by mycobacteria, for example, a nontuberculous mycobacterium such as Mycobacterium abscessus. In other aspects, the infection is caused by Escherichia coli, Pseudomonas aeruginosa, or methicillin-resistant Staphylococcus aureus (MRSA). Also disclosed are methods of identifying synthetic antimicrobial peptides against a pathogen with no known effective treatment using a library of synthetic peptides.